⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PCVX News
Vaxcyte, Inc. Common Stock
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
globenewswire.com
PCVX
Form 8-K
sec.gov
PCVX
Form 8-K
sec.gov
PCVX
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
globenewswire.com
PCVX
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
globenewswire.com
PCVX
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
globenewswire.com
PCVX
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
globenewswire.com
PCVX
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
globenewswire.com
PCVX
Vaxcyte Announces Pricing of $550 Million Public Offering
globenewswire.com
PCVX
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
globenewswire.com
PCVX